SCHEMBL23845148

SCHEMBL23845148

CS(=O)(=O)c1ccc(OC[C@@H](N)CCC(N)=O)cc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 5/20 0.39
▸ CA2 P00918 5/20 0.39
▸ CA9 Q16790 5/20 0.39
▸ CA12 O43570 3/20 0.39
▸ CA7 P43166 4/20 0.39
▸ CA4 P22748 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ GSR P00390 2/20 0.38
▸ S1PR4 O95977 2/20 0.38
▸ S1PR1 P21453 2/20 0.38
▸ S1PR5 Q9H228 2/20 0.38
▸ S1PR2 O95136 1/20 0.38
▸ S1PR3 Q99500 1/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ TRPV4 Q9HBA0 1/20 0.36
▸ EPHX1 P07099 1/20 0.36
▸ GRM4 Q14833 1/20 0.36
▸ MMP2 P08253 1/20 0.36
▸ MMP9 P14780 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL23833104 0.99 CA1 (0.41) CA1CA2CA9CA12CA7
Hydrochloric Acid SCHEMBL23833102 0.99 CA1 (0.41) CA1CA2CA9CA12CA7
SCHEMBL27015262 0.86 GPR88 (0.40) CA1CA2CA9CA12CA7
SCHEMBL23845133 0.84 PRMT5 (0.39) TRPV4
Hydrochloric Acid SCHEMBL23832958 0.83 PRMT5 (0.39) TRPV4
Hydrochloric Acid SCHEMBL23832959 0.83 PRMT5 (0.39) TRPV4
SCHEMBL23833338 0.76 CA2 (0.45) CA1CA2CA9CA12CA7
SCHEMBL23833336 0.76 CA2 (0.45) CA1CA2CA9CA12CA7
SCHEMBL6159 0.74 PDE4A (0.43) CA1CA2CA9CA12CA7
SCHEMBL29813063 0.72 LMNA (0.56) CA1CA2CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 — — US disclosed
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 — — US disclosed
WO-2021188696-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 CA1 2752/4885CA2 3372/4885CA9 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback